Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LONRF2 pseudogene 1 (LONRF2P1), also known as "LON peptidase N-terminal domain and ring finger 2 pseudogene 1," is classified as a pseudogene, indicating it is a non-protein-coding segment of DNA that resembles the functional paralog LONRF2 but does not encode an active protein product[3][10]. Pseudogenes typically originate through gene duplication or retrotransposition events and often accumulate mutations that disrupt their coding capacity[6]. While some pseudogenes can have regulatory roles at the DNA or RNA level influencing gene expression, there is currently no scientific evidence supporting a direct therapeutic, enzymatic, receptor, or transporter target role for LONRF2P1 specifically[3][6][10]. The canonical, functional gene LONRF2 encodes a ubiquitin ligase involved in protein quality control and neurodegeneration, but LONRF2P1 lacks established protein- or disease-related functionality[1][7][10]. No interacting drugs, mechanisms of action, or clinical utility for biomarker or safety monitoring are documented for this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LON peptidase N-terminal domain and ring finger 2 pseudogene 1 (LONRF2P1).